Evidence map›Paper›PMID 42129296›Full record

ArticleEuropean journal of human genetics : EJHG2026

Optimising rare tumour risk syndromes care: clinical insights and the PREVENTABLE socioeconomic framework.

Sara B Pereira, Liliana Sousa, Ricardo Amorim, Luzia Garrido, Rita Barbosa-Matos, Bárbara Peleteiro, Stefan Aretz, Judith Balmaña, Joan Brunet, Claude Houdayer and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sara B Pereira *i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Liliana Sousa *i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Ricardo Amorimi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Luzia Garridoi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Rita Barbosa-Matosi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Bárbara PeleteiroFaculdade de Medicina da Universidade do Porto, Porto, Portugal.
Stefan AretzEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID no. 739547, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-5228-1890
Judith BalmañaEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID no. 739547, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-0762-6415
Joan BrunetEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID no. 739547, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0003-1945-3512
Claude HoudayerEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID no. 739547, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-5190-0389
Svetlana Bajalica-LagercrantzEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID no. 739547, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-7175-7102
Igor LopesSociedade Portuguesa de Inovação, Porto, Portugal.ORCID http://orcid.org/0000-0001-9047-2711
Judite GonçalvesNOVA School of Business and Economics, NOVA University of Lisbon, Carcavelos, Portugal.
Nuno Teixeira MarcosIPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.
Marta M MarquesComprehensive Health Research Centre (CHRC), NOVA National School of Public Health, NOVA University of Lisbon, Lisbon, Portugal.
Céu MateusDivision of Health Research, Lancaster University, Bailrigg, Lancaster, UK.ORCID http://orcid.org/0000-0001-6219-219X
Laurène MatheyEuropean Health Management Association, Brussels, Belgium.
Imma PratsGirona Biomedical Research Institute Dr. Josep Trueta (IDIBGI), Girona, Spain.
Nuno RibeiroIPATIMUP - Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-5829-7367
Janneke H M Schuurs-HoeijmakersEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID no. 739547, Nijmegen, The Netherlands.
Jean-Christophe TheryDepartment of Medical Oncology, Center Henri Becquerel, University of Medicine of Rouen, Rouen, France.
Andrew TitmanDivision of Health Research, Lancaster University, Bailrigg, Lancaster, UK.ORCID http://orcid.org/0000-0003-2084-0720
Hildegunn H VettiEuropean Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) - Project ID no. 739547, Nijmegen, The Netherlands.ORCID http://orcid.org/0000-0002-9876-576X
Ana AzevedoFaculdade de Medicina da Universidade do Porto, Porto, Portugal.
PREVENTABLE Consortium
Carla Oliveirai3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal. carlaol@i3s.up.pt.ORCID http://orcid.org/0000-0001-8340-2264

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42129296
PMCPMC13549975

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.